HRP20161344T1 - Novi citostatski 7-deazapurinski nukleozidi - Google Patents

Novi citostatski 7-deazapurinski nukleozidi Download PDF

Info

Publication number
HRP20161344T1
HRP20161344T1 HRP20161344TT HRP20161344T HRP20161344T1 HR P20161344 T1 HRP20161344 T1 HR P20161344T1 HR P20161344T T HRP20161344T T HR P20161344TT HR P20161344 T HRP20161344 T HR P20161344T HR P20161344 T1 HRP20161344 T1 HR P20161344T1
Authority
HR
Croatia
Prior art keywords
compound according
alkyl
halo
heteroaryl
hydrogen
Prior art date
Application number
HRP20161344TT
Other languages
English (en)
Croatian (hr)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of HRP20161344T1 publication Critical patent/HRP20161344T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HRP20161344TT 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi HRP20161344T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
PCT/CZ2009/000004 WO2009089804A1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides
EP09702842.7A EP2231689B1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Publications (1)

Publication Number Publication Date
HRP20161344T1 true HRP20161344T1 (hr) 2016-11-18

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161344TT HRP20161344T1 (hr) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi
HRP20181774TT HRP20181774T1 (hr) 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181774TT HRP20181774T1 (hr) 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi

Country Status (18)

Country Link
US (1) US8093226B2 (https=)
EP (2) EP3133080B1 (https=)
JP (2) JP5485172B2 (https=)
CN (1) CN101977923B (https=)
AU (1) AU2009204568B2 (https=)
CA (1) CA2711384C (https=)
CY (2) CY1118104T1 (https=)
DK (2) DK2231689T3 (https=)
ES (2) ES2693551T3 (https=)
HR (2) HRP20161344T1 (https=)
HU (2) HUE041598T2 (https=)
LT (2) LT2231689T (https=)
NZ (1) NZ586610A (https=)
PL (2) PL2231689T3 (https=)
PT (2) PT2231689T (https=)
SI (2) SI3133080T1 (https=)
TR (1) TR201815961T4 (https=)
WO (1) WO2009089804A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
KR101817221B1 (ko) * 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114008064A (zh) * 2019-06-18 2022-02-01 大鹏药品工业株式会社 具有吡咯并嘧啶骨架的新型的磷酸酯化合物或其药学上可接受的盐
CN115515593A (zh) * 2020-02-17 2022-12-23 勒芬天主教大学 作为药物的新的6-取代的7-脱氮嘌呤和相应的核苷
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (https=) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
EP1804812A4 (en) * 2004-10-21 2009-09-02 Merck & Co Inc FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
HUE041598T2 (hu) 2019-05-28
JP2011509949A (ja) 2011-03-31
HUE030767T2 (en) 2017-05-29
CN101977923B (zh) 2014-10-08
CN101977923A (zh) 2011-02-16
EP2231689B1 (en) 2016-07-20
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
SI2231689T1 (sl) 2016-11-30
ES2598503T3 (es) 2017-01-27
PL2231689T3 (pl) 2017-01-31
TR201815961T4 (tr) 2018-11-21
EP3133080A1 (en) 2017-02-22
NZ586610A (en) 2012-08-31
AU2009204568B2 (en) 2013-10-03
SI3133080T1 (sl) 2018-12-31
LT3133080T (lt) 2018-11-12
LT2231689T (lt) 2016-10-25
ES2693551T3 (es) 2018-12-12
DK2231689T3 (en) 2016-09-19
PL3133080T3 (pl) 2018-12-31
AU2009204568A1 (en) 2009-07-23
JP5485172B2 (ja) 2014-05-07
US8093226B2 (en) 2012-01-10
CA2711384A1 (en) 2009-07-23
EP3133080B1 (en) 2018-08-01
JP2014058567A (ja) 2014-04-03
CY1118104T1 (el) 2017-06-28
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
CA2711384C (en) 2016-07-26
US20090203637A1 (en) 2009-08-13
CY1121364T1 (el) 2020-05-29
EP2231689A1 (en) 2010-09-29
PT2231689T (pt) 2016-10-07

Similar Documents

Publication Publication Date Title
HRP20161344T1 (hr) Novi citostatski 7-deazapurinski nukleozidi
JP2011509949A5 (https=)
HRP20210365T1 (hr) Dna-pk inhibitori
IL276711B1 (en) Arginase inhibitors and methods of use thereof
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
HRP20170627T1 (hr) Derivati 2-metilmorfolin pirido-, pirazo- i pirimido-pirimidina kao inhibitori mtor
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
HRP20131021T1 (hr) Novi 7-deazapurin nukleozidi za terapijske uporabe
ME02558B (me) Inhibitori replikacije virusa gripa
MY151986A (en) Adamantyl diamide derivatives and uses of same
HRP20161103T1 (hr) Kemijski spojevi
ME02423B (me) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
JP2016504365A5 (https=)
WO2006095159A8 (en) (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2008057856A3 (en) Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
RU2012144614A (ru) Кристаллические формы макролида и их применение